Product Description
Mechanisms of Action: COMT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | France | Germany | Greece | Hong Kong | Hungary | India | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Primus
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Forearm Injuries|Pelvic Pain|Edema|Varicose Veins|Chronic Pain|Lymphedema|Anal Fistula|Postthrombotic Syndrome|Postphlebitic Syndrome|Venous Thrombosis|Venous Insufficiency|Rectal Fistula
Phase 3: Infertility|Edema|Chronic Pain|Venous Insufficiency|Ovarian Hyperstimulation Syndrome|Cellulite|Lipodystrophy|Hemorrhoids|Peptic Ulcer|Common Bile Duct Diseases|Hypertension, Renal|Pelvic Pain|Inflammation|Leukocyte Disorders|Ovarian Diseases|Kidney Diseases|Uterine Diseases|Abdominal Pain|Varicose Veins|Depressive Disorder|Vaginal Diseases|Bile Reflux|Peripheral Nervous System Diseases|Fatty Liver, Alcoholic|Breast Cancer|Hepatitis, Alcoholic|Breast Diseases|Non-alcoholic Steatohepatitis|Colitis, Ulcerative|Arthritis, Rheumatoid
Phase 1: Coronavirus Infections|Acute Respiratory Distress Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| RyazanSMU | N/A |
Active, not recruiting |
Varicose Veins|Edema |
2026-04-01 |
2024-04-17 |
Primary Endpoints|Treatments |
|
| NCT06811220 | P3 |
Not yet recruiting |
Breast Cancer|Breast Diseases|Peripheral Nervous System Diseases |
2025-12-31 |
2025-02-07 |
||
| NCT05756179 | P3 |
Recruiting |
Arthritis, Rheumatoid |
2025-09-01 |
2024-09-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
| PVDUS-01 | N/A |
Not yet recruiting |
Scleroderma, Diffuse|Skin Ulcer|Scleroderma, Systemic|Scleroderma, General |
2025-07-15 |
2024-07-23 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
|
| NCT06753448 | N/A |
Enrolling by invitation |
Total Knee Arthroplasty|Venous Insufficiency |
2025-06-01 |
2025-05-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
| VENOTREAT | P3 |
Recruiting |
Bile Reflux|Vaginal Diseases|Kidney Diseases|Chronic Pain|Varicose Veins|Abdominal Pain|Ovarian Diseases|Uterine Diseases|Pelvic Pain|Edema|Common Bile Duct Diseases|Leukocyte Disorders|Depressive Disorder|Hypertension, Renal|Inflammation |
2025-01-01 |
2024-09-06 |
||
| N202309013 | P4 |
Completed |
Anal Fistula|Rectal Fistula |
2025-01-01 |
2025-05-17 |
Primary Completion Date|Primary Endpoints |
|
| ESPINS | N/A |
Completed |
Hypertension |
2024-11-15 |
2025-03-28 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| diosmin peptic ulcer | P3 |
Unknown status |
Peptic Ulcer |
2024-06-01 |
2025-06-03 |
Primary Endpoints|Treatments|Trial Status |
|
| Aya Mohammed | N/A |
Completed |
Ovarian Hyperstimulation Syndrome |
2024-02-01 |
2025-01-08 |
Primary Endpoints|Treatments |
|
| NCT05626166 | P3 |
Unknown status |
Colitis, Ulcerative |
2023-11-01 |
2025-04-02 |
Primary Endpoints|Treatments|Trial Status |
|
| OPGIE/0122/FS | N/A |
Unknown status |
Hemorrhoids |
2023-10-15 |
2025-02-04 |
Primary Endpoints|Treatments|Trial Status |
|
| 3626MS202/6/23 | P3 |
Recruiting |
Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis |
2023-10-10 |
2023-07-13 |
Primary Endpoints|Treatments |
|
| ChiCTR2100049077 | N/A |
Not yet recruiting |
Total Knee Arthroplasty |
2022-12-30 |
|||
| MDA-1 | P4 |
Completed |
Lymphedema |
2022-08-03 |
2022-08-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| ENDPCS | P4 |
Unknown status |
Chronic Pain|Pelvic Pain|Varicose Veins |
2022-07-31 |
2022-10-06 |
||
| HP8834-01 | P1 |
Completed |
Acute Respiratory Distress Syndrome |
2021-12-14 |
50% |
2022-02-17 |
Primary Endpoints|Treatments|Trial Status |
| NIS-ВЕН-19.03 | N/A |
Completed |
Varicose Veins |
2021-08-28 |
2022-04-01 |
||
| NCT04452799 | P1 |
Unknown status |
Coronavirus Infections |
2020-10-01 |
2022-06-03 |
Primary Endpoints|Treatments|Trial Status |
|
| ChiCTR1900022531 | N/A |
Not yet recruiting |
Unknown |
2020-08-01 |
|||
| ACTRN12614000535673 | P3 |
Recruiting |
Ovarian Hyperstimulation Syndrome |
2019-09-29 |
2024-08-29 |
Treatments |
|
| RIDILOTT-DVT | P4 |
Completed |
Postthrombotic Syndrome|Venous Thrombosis|Postphlebitic Syndrome |
2019-07-31 |
2019-03-22 |
Treatments |
|
| ChiCTR1800019613 | N/A |
Recruiting |
Hemorrhoids |
2019-05-01 |
|||
| DIVC-01-12-17 | P4 |
Completed |
Venous Insufficiency |
2018-03-20 |
2019-03-22 |
||
| ACTRN12618001033235 | P4 |
Completed |
Forearm Injuries|Edema |
2018-01-28 |
2024-08-29 |
Treatments |